[Laboratory's controls of antifungal treatment by the fluconazole of the candidiasis in immunocompromised patients].
The use of antifungal drugs in immunocompromised patients impose to the laboratory the control of the efficacy of these therapy. With fluconazole, one of the most recent antifungal agents these control use a special method (Central Research Pfizer) different of those they are used with others antifungals. We have comparatively tested, using MIC technic four broth mediums (High Resolution medium (Oxoid) YMB (Difco) YNB dextrose (Autobac) and Casitone) and three agar mediums (HR, YMA, Casitone) incubated at 28 degrees C for 24 and 48 h. The strains of yeasts are isolated from oro-pharyngeal prelevements on HIV antibody positive patients observed during six to twelve months and eventually treated by fluconazole. Sixty patients are controlled, 33 give one or more positive cultures with 74 strains of C. albicans and four other yeasts. By determination of the MICs with seven different methods we find any resistant strains with the MICs range from 3.12 to 12.5 or 25 micrograms/ml.
Blancard
A
A
Laboratoire de Parasitologie, CHR de la Timone, Marseille.
Moulin-Traffort
J
J
Regli
P
P
Sarzier
J M
JM
Quilici
M
M
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D002176:Candida albicans / Q000187:drug effects* / Q000302:isolation & purification; D002177:Candidiasis / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology; D004305:Dose-Response Relationship, Drug; D015725:Fluconazole / Q000494:pharmacology* / Q000627:therapeutic use; D015658:HIV Infections / Q000150:complications*; D006801:Humans; D008991:Monitoring, Physiologic; D009894:Opportunistic Infections / Q000150:complications / Q000188:drug therapy* / Q000382:microbiology
D015725:Fluconazole
Apport du laboratoire dans la surveillance du traitement antifongique par le fluconazole des candidoses chez les immunodéprimés.